Maravai Lifesciences Holdings (MRVI) Amortization of Deferred Charges (2020 - 2025)

Maravai Lifesciences Holdings' Amortization of Deferred Charges history runs 7 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• In Q1 2026, Amortization of Deferred Charges fell 26.57% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $1.1 million (down 89.19% YoY), while the FY2025 annual figure was $1.7 million, down 80.5% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $1.6 million, up from -$5.0 million in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $3.5 million in Q2 2024, with the low at -$5.0 million in Q4 2025.
• The 5-year median for Amortization of Deferred Charges is $1.6 million (2026), against an average of $1.0 million.
• The sharpest annual moves came in 2024 and 2025: Amortization of Deferred Charges surged 204.83% in 2024, then sank 332.67% in 2025.
• Maravai Lifesciences Holdings' Amortization of Deferred Charges stood at $654000.0 in 2022, then advanced by 13.61% to $743000.0 in 2023, then surged by 190.44% to $2.2 million in 2024, then tumbled by 332.67% to -$5.0 million in 2025, then surged by 131.99% to $1.6 million in 2026.
• Business Quant data shows MRVI's Amortization of Deferred Charges at $1.6 million in Q1 2026, -$5.0 million in Q4 2025, and $2.3 million in Q3 2025.